Payment overview · 2025
General Payments
$309.65
15 reported records · 12 companies
Healthcare provider profile · identity verified
Emily Niemi
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · LINCOLN PARK, MI · NPI 1386395895
Verified facts
What the public records show
CMS Open Payments records show Emily Niemi received $309.65 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.88 | 14.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.75 | 14.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.22 | 9.4% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $28.10 | 9.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.62 | 8.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.35 | 8.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.98 | 8.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.20 | 6.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.83 | 6.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.66 | 5.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.74 | 5.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.32 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $309.65 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.88 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 630 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 93 |
| Omeprazole | Omeprazole | 351 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 344 | 90 |
| Lisinopril | Lisinopril | 335 | 72 |
| Metformin Hcl | Metformin Hcl | 307 | 68 |
| Furosemide | Furosemide | 287 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 238 | 64 |
| Gabapentin | Gabapentin | 220 | 42 |
| Ibuprofen | Ibuprofen | 201 | 54 |
| Tramadol Hcl | Tramadol Hcl | 191 | 28 |
| Losartan Potassium | Losartan Potassium | 177 | 41 |
| Meloxicam | Meloxicam | 171 | 39 |
| Simvastatin | Simvastatin | 168 | 43 |
| Famotidine | Famotidine | 157 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 31 |
| Potassium Chloride | Potassium Chloride | 156 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 45 |
| Trazodone Hcl | Trazodone Hcl | 150 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 141 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 141 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 128 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 29 |
| Montelukast Sodium | Montelukast Sodium | 123 | 22 |
| Eliquis | Apixaban | 122 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 29 |
| Sertraline Hcl | Sertraline Hcl | 116 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 28 |
| Ozempic | Semaglutide | 111 | 17 |
| Alprazolam | Alprazolam | 110 | 14 |
| Pregabalin | Pregabalin | 103 | 17 |
| Farxiga | Dapagliflozin Propanediol | 93 | 23 |
| Carvedilol | Carvedilol | 90 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 17 |
| Naproxen | Naproxen | 83 | 24 |
| Mounjaro | Tirzepatide | 81 | 16 |
| Hydrocortisone | Hydrocortisone | 80 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 14 |
| Topiramate | Topiramate | 77 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 19 |
| Allopurinol | Allopurinol | 72 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 21 |
| Vraylar | Cariprazine Hcl | 72 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 20 |
| Ketoconazole | Ketoconazole | 71 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 68 | 12 |
| Alendronate Sodium | Alendronate Sodium | 67 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 22 |
| Nystatin | Nystatin | 66 | 28 |
| Lidocaine | Lidocaine | 64 | 11 |
| Clonidine Hcl | Clonidine Hcl | 61 | 12 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 60 | 14 |
| Atenolol | Atenolol | 57 | 12 |
| Donepezil Hcl | Donepezil Hcl | 57 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 15 |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Diazepam | Diazepam | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Methocarbamol | Methocarbamol | 49 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 13 |
| Jardiance | Empagliflozin | 45 | 11 |
| Baclofen | Baclofen | 43 | 13 |
| Prednisone | Prednisone | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 12 |
| Mupirocin | Mupirocin | 42 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 11 |
| Loperamide | Loperamide Hcl | 39 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | 11 |
| Acyclovir | Acyclovir | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 13 |
| Glipizide | Glipizide | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | 14 |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Ammonium Lactate | Ammonium Lactate | 27 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Tramadol Hcl Er | Tramadol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $309.65 · 15 records | PFIZER INC. | AIRSUPRA, BRIXADI, CAPLYTA, Cologuard Collection Kit, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TONMYA, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, ZAVZPRET, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error